✣OncoGonFROM DISCOVERY TO IMPACT
HomeAssetsTriage & Prioritisation
3D Tumour IntelligenceExperimentsImagingSegmentation & QCResponse AnalysisAI Analysis (OSIEL)
Qualified AssetsIndustry & Data RoomCollaborationReports & Insights
Admin
HomeQualified Assets
RESEARCH → TECHNOLOGY TRANSFER

Qualified Assets

Review scientifically supported assets, qualification evidence, governance gates, and commercialisation readiness.

Qualification Candidates18Approaching formal review
Under Review9Human assessment
Qualified36Human decisions
Needs Evidence7Gaps unresolved
TTO Review12Governance queue
Partner-Ready18Disclosure still controlled
Scientific approval ≠ training eligibility ≠ asset qualification ≠ industry readiness ≠ external disclosure. Qualification requires authorised human review.

Qualification Pipeline

Illustrative portfolio stages · no automatic progression

01Candidate18
02Evidence Review9
03Scientific Qualification36
04TTO Review12
05Commercial Readiness18
06Partner-Ready18

Qualification Registry

3 current records in this view

AssetCancer IndicationScientific StatusEvidenceQualificationCommercialIP StatusTTO OwnerQualified OnNext Action
OGC-2401Novel small moleculeBreast CancerTNBC, HER2-Scientific Review Pending85%Qualification Review72%Under AssessmentTTO Office—Complete replicate validation
OGC-NS-321CNS penetrant agentGlioblastomaIDH-wildtypeScientifically Approved72%Qualified81%Disclosure FiledMs. N. Adams2026-09-18Prepare industry package
OGC-LU-104Targeted degraderLung CancerNSCLCUnder Review55%Needs Evidence58%Not ReviewedTTO Office—Complete scientific evidence

Qualification Context

OGC-2401 · Novel small molecule

Open workspace
Scientific stateScientific Review Pending
QualificationQualification Review
Evidence packageEP-OGC2401-v1.4
Evidence readiness85%
Commercial readiness72%

Governance gates

Passed
Scientific evidence reviewedScientific Criteria · EV-024Dr. S. Mokoena · 2026-10-03
Passed
Primary validation completedScientific Criteria · BC-001Dr. S. Mokoena · 2026-10-03
Passed
Critical QC passedData Integrity · IMG-BC001-017Dr. S. Mokoena · 2026-10-03
Pending
Independent reviewer approvalIndependent Review · Scientific review pendingDr. J. Patel · 2026-10-03
Pending
Evidence package version lockedEvidence Criteria · EP-OGC2401-v1.4Dr. S. Mokoena · 2026-10-03

Outstanding requirements

Replicate confirmation incomplete

Independent reviewer sign-off pending

Rights and data ownership review pending

IP / Disclosure

IP assessmentUnder Assessment

OSIEL Scientific Context

Illustrative OSIEL synthesis: strong 3D response and reviewed image QC; replicate, pathway and PK/PD evidence require additional human review.

Inspect in OSIEL
Open Qualification Workspace

Qualification History

Qualification review opened2026-10-03 · TTO Office
Evidence package updated2026-10-02 · Dr. S. Mokoena
IP assessment requested2026-09-30 · Ms. N. Adams